Faster global financial news!
Biopharmaceuticals
-
China's A-share market saw its three major indices rise collectively in early trading, with the ChiNext Index once gaining over 1%. Hong Kong's Hang Seng Tech Index surged before pulling back to losses, while the Biotech Index soared nearly 5%. Crude oil prices fell sharply by 6%.
On September 21st, A-shares collectively rose in early trading, with the Shanghai Composite Index up 0.50%, the Shenzhen Component Index up 0.80%, and the ChiNext Index up 1.29%. The biomedical sector
-
China has released a new five-year plan for biomedicine, aiming to capture 25% of the global market for first-in-class drugs by 2030.
Chinese authorities stated on Friday that, under a new five-year plan, China aims to become a global biopharmaceutical powerhouse by 2030, with goals to achieve breakthroughs in key technologies and c
-
China's A-share market saw the Shanghai Composite Index fall by 0.38% in early trading, with the biomedical sector surging. CRO and innovative drug stocks rose sharply. Hong Kong stocks, including the Hang Seng Index and Hang Seng Tech Index, both fell by over 1%, with major tech stocks generally declining.
On the morning of September 17, A-share major indices opened lower and then fluctuated downwards. The Shanghai Composite Index fell by 0.38%, the Shenzhen Component Index remained flat, and the ChiNex
-
Hong Kong to unveil first five-year plan next week, targeting biomedicine powerhouse status; GSK expresses interest in region's biotech development on Wednesday
Hong Kong's inaugural five-year plan, set to be unveiled next week, will focus on establishing the city as a biomedicine powerhouse, signaling closer medical cooperation across the Greater Bay Area. G
-
WuXi AppTec's stock price surged 100% to an all-time high, as investors bet on its continued core position in the global drug supply chain.
WuXi AppTec's stock price hit a record high last week, doubling its January level, despite the U.S. Pentagon listing it as a Chinese military company, which could lead some American clients to withdra
-
China's A-share market saw its three major indices rise collectively in early trading, with the ChiNext Index once gaining over 1%. Hong Kong's Hang Seng Tech Index surged before pulling back to losses, while the Biotech Index soared nearly 5%. Crude oil prices fell sharply by 6%.
On September 21st, A-shares collectively rose in early trading, with the Shanghai Composite Index up 0.50%, the Shenzhen Component Index up 0.80%, and the ChiNext Index up 1.29%. The biomedical sector
-
China has released a new five-year plan for biomedicine, aiming to capture 25% of the global market for first-in-class drugs by 2030.
Chinese authorities stated on Friday that, under a new five-year plan, China aims to become a global biopharmaceutical powerhouse by 2030, with goals to achieve breakthroughs in key technologies and c
-
China's A-share market saw the Shanghai Composite Index fall by 0.38% in early trading, with the biomedical sector surging. CRO and innovative drug stocks rose sharply. Hong Kong stocks, including the Hang Seng Index and Hang Seng Tech Index, both fell by over 1%, with major tech stocks generally declining.
On the morning of September 17, A-share major indices opened lower and then fluctuated downwards. The Shanghai Composite Index fell by 0.38%, the Shenzhen Component Index remained flat, and the ChiNex
-
Hong Kong to unveil first five-year plan next week, targeting biomedicine powerhouse status; GSK expresses interest in region's biotech development on Wednesday
Hong Kong's inaugural five-year plan, set to be unveiled next week, will focus on establishing the city as a biomedicine powerhouse, signaling closer medical cooperation across the Greater Bay Area. G
-
WuXi AppTec's stock price surged 100% to an all-time high, as investors bet on its continued core position in the global drug supply chain.
WuXi AppTec's stock price hit a record high last week, doubling its January level, despite the U.S. Pentagon listing it as a Chinese military company, which could lead some American clients to withdra
- No data
Biopharmaceuticals
24H Trending
-
1
Dogecoin (DOGE): Current Market Performance and Analysis of Future Influencing Factors
-
2
China's quant investing sector produced 18 funds with over $1.5 billion AUM each this year
-
3
Goldman Sachs trading desk head says long-term US Treasuries "unloved," 10-year yield reaches 5.34%.
-
4
PUNDIX: Bridging Crypto and Retail, Strategic Transformation to AI and Web3
-
5
Current Status of Virtual Currency Trading Regulation and Risk Warnings in Mainland China
-
6
Ethereum (ETH) All-Time High RMB Price and Value Drivers Analysis
-
7
Tamadoge (TAMA) Project Status and Historical Review
-
8
BSCPAD Token Historical Price Review: All-Time High and Low Analysis
-
9
Cryptocurrency Exchange Fee Analysis and Mainstream App Review
-
10
Samsung may raise Galaxy S27 prices more than planned due to rising memory costs, following recent S26 price increases
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
